JP2023521219A5 - - Google Patents
Info
- Publication number
- JP2023521219A5 JP2023521219A5 JP2022562561A JP2022562561A JP2023521219A5 JP 2023521219 A5 JP2023521219 A5 JP 2023521219A5 JP 2022562561 A JP2022562561 A JP 2022562561A JP 2022562561 A JP2022562561 A JP 2022562561A JP 2023521219 A5 JP2023521219 A5 JP 2023521219A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- molecule
- amino acid
- hla
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025153952A JP2026009916A (ja) | 2020-04-14 | 2025-09-17 | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009853P | 2020-04-14 | 2020-04-14 | |
| US63/009,853 | 2020-04-14 | ||
| PCT/CA2021/050340 WO2021207823A1 (en) | 2020-04-14 | 2021-03-15 | Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153952A Division JP2026009916A (ja) | 2020-04-14 | 2025-09-17 | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521219A JP2023521219A (ja) | 2023-05-23 |
| JP2023521219A5 true JP2023521219A5 (https=) | 2024-02-29 |
| JP7822953B2 JP7822953B2 (ja) | 2026-03-03 |
Family
ID=78083452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562561A Active JP7822953B2 (ja) | 2020-04-14 | 2021-03-15 | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
| JP2025153952A Pending JP2026009916A (ja) | 2020-04-14 | 2025-09-17 | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153952A Pending JP2026009916A (ja) | 2020-04-14 | 2025-09-17 | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230287070A1 (https=) |
| EP (1) | EP4136099A4 (https=) |
| JP (2) | JP7822953B2 (https=) |
| KR (1) | KR20220167288A (https=) |
| CN (1) | CN115397842A (https=) |
| AU (1) | AU2021256477A1 (https=) |
| BR (1) | BR112022020376A2 (https=) |
| CA (1) | CA3173666A1 (https=) |
| IL (1) | IL296881A (https=) |
| MX (1) | MX2022012758A (https=) |
| WO (1) | WO2021207823A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114045341B (zh) * | 2021-11-30 | 2024-03-01 | 中南大学 | 口腔黏膜下纤维化恶性进展或其所致口腔癌的早期诊断和/或预后生物标志物的应用及产品 |
| WO2024077376A1 (en) * | 2022-10-11 | 2024-04-18 | Université de Montréal | Novel tumor-specific antigens for myeloid leukemia and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| ES2532896T5 (es) * | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| EP2576614A4 (en) * | 2010-05-24 | 2013-11-13 | Phosimmune Inc | CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS |
| SG11201507883SA (en) * | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| HRP20191671T1 (hr) * | 2014-05-09 | 2019-12-13 | Immatics Biotechnologies Gmbh | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |
| HRP20200967T1 (hr) * | 2014-06-20 | 2020-10-16 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll) |
| GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| EP3277841A1 (en) * | 2015-03-31 | 2018-02-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New biomarker for outcome in aml |
| WO2016209079A1 (en) * | 2015-06-24 | 2016-12-29 | Aimm Therapeutics B.V. | Aml antigens and uses thereof |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| CN109071605A (zh) * | 2016-04-06 | 2018-12-21 | 伊玛提克斯生物技术有限公司 | 用于aml和其他癌症免疫治疗的新型肽和肽组合物 |
| TWI796299B (zh) * | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| EA201992416A1 (ru) * | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
| US10925947B2 (en) * | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| CN112639136B (zh) * | 2018-08-30 | 2024-08-02 | 蒙特利尔大学 | 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法 |
| TW202024121A (zh) * | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
-
2021
- 2021-03-15 CA CA3173666A patent/CA3173666A1/en active Pending
- 2021-03-15 WO PCT/CA2021/050340 patent/WO2021207823A1/en not_active Ceased
- 2021-03-15 MX MX2022012758A patent/MX2022012758A/es unknown
- 2021-03-15 AU AU2021256477A patent/AU2021256477A1/en active Pending
- 2021-03-15 US US17/916,539 patent/US20230287070A1/en active Pending
- 2021-03-15 EP EP21788987.2A patent/EP4136099A4/en active Pending
- 2021-03-15 KR KR1020227036244A patent/KR20220167288A/ko active Pending
- 2021-03-15 IL IL296881A patent/IL296881A/en unknown
- 2021-03-15 CN CN202180028396.9A patent/CN115397842A/zh active Pending
- 2021-03-15 JP JP2022562561A patent/JP7822953B2/ja active Active
- 2021-03-15 BR BR112022020376A patent/BR112022020376A2/pt unknown
-
2025
- 2025-09-17 JP JP2025153952A patent/JP2026009916A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7559120B2 (ja) | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 | |
| TWI764886B (zh) | 轉染 t 細胞和 t 細胞受體用於癌症免疫治療 | |
| JP6913032B2 (ja) | 共通ネオ抗原 | |
| CN108778291B (zh) | 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法 | |
| JP2023106599A5 (https=) | ||
| JP2022527267A5 (https=) | ||
| JP2022523554A5 (https=) | ||
| JP2022524994A5 (https=) | ||
| JP2022523552A5 (https=) | ||
| JP2022524993A5 (https=) | ||
| JP2023521219A5 (https=) | ||
| JP2022523971A5 (https=) | ||
| AU2020231694A1 (en) | T cell receptors and methods of use thereof | |
| JP2022524992A5 (https=) | ||
| JP2024535853A5 (https=) | ||
| JP2022543059A5 (https=) | ||
| CA3146298A1 (en) | T cell receptors and methods of use thereof | |
| AU2020322247A1 (en) | T cell receptors and methods of use thereof | |
| EP4004219A1 (en) | T cell receptors and methods of use thereof | |
| JP2022543058A5 (https=) | ||
| CN113929767B (zh) | 具有高亲和力的t细胞受体及其用途 | |
| JP2024536647A (ja) | 操作されたｔｃｒ複合体及びそれを使用する方法 | |
| JP2024527620A5 (https=) | ||
| US20260042827A1 (en) | Anti-wt1 antigen-binding proteins and uses thereof | |
| Janik et al. | Phase I trial of siplizumab in CD2-positive lymphoproliferative disease |